Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Overview

Alleviation of allergic symptoms induced by house dust mites when using the medical device AM-301. This clinical investigation explores the efficacy and safety of AM-301 when used to reduce symptoms of house dust mite sufferers. The primary objective is to compare the efficacy of AM-301 Device between treated and non-treated subjects in the treatment of perennial allergic rhinitis (PAR).

Full Title of Study: “Pivotal, Randomized, Open-Label, 3-Period Crossover Study to Assess the Efficacy and Safety of AM-301 on Allergic Symptoms During House Dust Mite Challenge in an Exposure Chamber in Study Participants With Perennial Allergic Rhinitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 28, 2022

Interventions

  • Device: Treatment A
    • Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens. One Spray of AM-301 per nostril
  • Device: Treatment B
    • Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens. Two Sprays of AM-301 per nostril (with different spray angles)
  • Other: Treatment C
    • No treatment

Arms, Groups and Cohorts

  • Experimental: Sequence 1
    • Treatment sequence for the 3 treatment exposure visits is ABC.
  • Experimental: Sequence 2
    • Treatment sequence for the 3 treatment exposure visits is BCA.
  • Experimental: Sequence 3
    • Treatment sequence for the 3 treatment exposure visits is CAB.
  • Experimental: Sequence 4
    • Treatment sequence for the 3 treatment exposure visits is ACB.
  • Experimental: Sequence 5
    • Treatment sequence for the 3 treatment exposure visits is BAC.
  • Experimental: Sequence 6
    • Treatment sequence for the 3 treatment exposure visits is CBA.

Clinical Trial Outcome Measures

Primary Measures

  • Changes from baseline in Total Nasal Symptom Score (TNSS) at each post-dose assessment time points (0 to 3 hours) at Visit 3, Visit 4 and Visit 5
    • Time Frame: Day 8 to Day 22
    • Total Nasal Symptom Score (TNSS) average from 20 – 180 min will be compared between treated and non-treated subjects. Scale is from 0 – 3, 0 meaning no symptoms and 3 severe symptoms. Assessed symptoms are: nasal congestion, runny nose, nasal itching and sneezing.

Secondary Measures

  • Difference of Total Nasal Symptom Score (TNSS) at individual timepoints during house dust mite challenge in the EEC (0-180 min) between single and double application of AM-301 and no treatment.
    • Time Frame: Day 8 to Day 22
    • Total Nasal Symptom Score (TNSS) average from 20 – 180 min will be compared between treated and non-treated subjects. Scale is from 0 – 3, 0 meaning no symptoms and 3 severe symptoms. Assessed symptoms are: nasal congestion, runny nose, nasal itching and sneezing.

Participating in This Clinical Trial

Main Inclusion Criteria:

  • Body mass index between 18.0 and 32.0 kg/m2 inclusive. – History of perennial allergic rhinitis to house dust mite for more than 1 year. – Positive Skin Prick Test (SPT) for Dermatophagoides pteronyssinus (der p) allergen at screening or within 12 months prior to the screening visit. Main Exclusion Criteria:

  • Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, urinalysis, vital signs, lung function at screening visit, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject's ability to participate in the study. – Use of any medication considered to have an influence on the outcome of the study during the EEC session, at the discretion of the Investigator and/or designee. – Recent nasal ulcers, mucosal erosion, nasal surgery, or nasal trauma, that might interfere with study results as determined by the Investigator and/or designee.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Altamira Medica Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Peter Couroux, MD, FRCPC, CPI, Principal Investigator, Cliantha Research

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.